Angiosarcoma is an aggressive malignancy that arises spontaneously or secondarily to ionizing radiation or chronic lymphoedema 1 . Previous work has identified aberrant angiogenesis, including occasional somatic mutations in angiogenesis signaling genes, as a key driver of angiosarcoma 1 . Here we employed whole-genome, whole-exome and targeted sequencing to study the somatic changes underpinning primary and secondary angiosarcoma. We identified recurrent mutations in two genes, PTPRB and PLCG1, which are intimately linked to angiogenesis. The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored predominantly truncating mutations in 10 of 39 tumors (26%). PLCG1, a signal transducer of tyrosine kinases, encoded a recurrent, likely activating p.Arg707Gln missense variant in 3 of 34 cases (9%). Overall, 15 of 39 tumors (38%) harbored at least one driver mutation in angiogenesis signaling genes. Our findings inform and reinforce current therapeutic efforts to target angiogenesis signaling in angiosarcoma.
We performed whole-genome sequencing of DNA from three angiosarcomas, along with paired normal DNA from the same cases. The somatic mutation burden of the three cases varied from 0.7-2.2 substitutions per megabase and 0.1-0.2 indels per megabase ( Supplementary Fig. 1 and Supplementary Tables 1-5 ). Remarkably, in two of the three angiosarcomas, we identified truncating mutations in the PTPRB (VE-PTP) gene, encoding a tyrosine phosphatase specific to the vascular endothelium that inhibits angiogenesis 2 . One tumor had a nonsense alteration (p.Glu1444*), and the other had both a nonsense (p.Cys1693*) and a missense (p.Tyr309Cys) alteration.
To explore this observation further, we extended our investigation to 36 angiosarcomas that we studied by whole-exome sequencing (n = 8) or by targeted sequencing of 360 cancer-related genes (n = 4; Supplementary Table 6 ) or 28 angiogenesis-related genes (n = 24; Supplementary Table 7 ). The entire footprint of PTPRB was sequenced to enable the identification of structural rearrangements in addition to coding point mutations. We also sequenced angiogenesisrelated genes in eight epithelioid hemangioendotheliomas, nine Kaposi sarcomas and two hemangiomas.
In total, we identified 14 PTPRB mutations in 10 of 39 angiosarcomas (26%), comprising 8 nonsense variants, 2 essential splice-site variants, 1 frameshift insertion and 3 missense variants ( Fig. 1) . No large deletions or rearrangements were identified, although the presence of small intragenic deletions cannot be excluded. All truncating mutations disrupted the coding sequence of PTPRB before or within the sequence encoding the tyrosine phosphatase domain. Two of the missense mutations (encoding p.Tyr309Cys and p.Trp130Arg substitutions) lie within the portion of PTPRB encoding the extracellular domain, the inhibition of which has been shown to disrupt PTPRB function 3 . The third missense mutation, encoding p.Pro1996Leu, affected the tyrosine phosphatase domain. The SIFT in silico prediction tool of variant effects ascribed deleterious consequences to these missense variants. No PTPRB mutations were identified in hemangioendothelioma, Kaposi sarcoma or hemangioma. Inactivating PTPRB mutations are also rare in other cancer types, as documented in the Catalogue of Somatic Mutations in Cancer (COSMIC) 4 , suggesting that PTPRB disruption is largely specific to angiosarcoma. Statistical analysis demonstrated that these truncating PTPRB mutations were extremely unlikely to have accumulated by chance in angiosarcoma (q = 1 × 10 −9 ), suggesting that inactivating PTPRB mutations are driver events. Notably, all PTPRB mutations were identified in tumors that were either known to be secondary and/or had MYC amplification, a biomarker of radiationassociated secondary angiosarcoma 5 (P = 0.005). In this group, the prevalence of PTPRB mutations was 45% (10/22 cases).
Four angiosarcomas harbored two different nonsynonymous PTPRB mutations each, including at least one truncating variant in each case. In two of these cases, both mutations were truncating, consistent with biallelic inactivation and suggesting that PTPRB operates as a recessive cancer gene. In six angiosarcomas, there was a single heterozygous PTPRB variant, five truncating and one missense, without evidence of loss of heterozygosity (LOH). The presence of a single detectable nonsynonymous mutation in 60% of tumors is not unusual for tumor suppressor genes (Supplementary Fig. 2 ). We analyzed published catalogs of somatic mutations in 4,073 tumors to determine the frequency of a second mutation, including LOH, co-occurring with a truncating mutation in established tumor suppressor genes. This analysis indicated that the pattern of mutation we observed in PTPRB is compatible with a recessive driver mechanism ( Supplementary Fig. 2 ). Nevertheless, we cannot exclude the possibility that other mechanisms, such as haploinsufficiency or dominantnegative effects, are operative.
PTPRB, a negative regulator of angiogenesis, is expressed exclusively in vascular endothelium, both during development and in adult tissues 2,6 . The encoded protein inhibits vascular endothelial growth factor receptor 2 (VEGFR2), vascular endothelial (VE)cadherin and angiopoietin signaling, thus acting as an integral modifier of angiogenesis 2,3,6-15 . In in vitro models of angiogenesis, PTPRB inhibition increases angiogenesis 12 . Ptprb-null mice die in utero and display severe vascular malformations 6 . Although the role of PTPRB as a negative regulator of angiogenesis is well established, it is not known whether PTPRB-driven angiogenesis can be inhibited through pharmacological VEGF inhibition. Consequently, we investigated the effects of knockdown of PTPRB on primary cultures of human umbilical vein endothelial cells (HUVECs). Silencing of PTPRB via small interfering RNA (siRNA) induced features of angiogenesis such as spheroid sprouting after 24 h and spindle-like morphology. In the presence of sunitinib or vatalanib, inhibitors of the VEGFR2 kinase, these features were abolished ( Fig. 2 and Supplementary Fig. 3 ). These findings in HUVECs, a model of the vascular endothelium, provide a rationale for exploring whether PTPRB mutation status correlates with treatment response to anti-angiogenic agents.
To explore the contribution of other genes in angiosarcoma, we analyzed variant data from 15 angiosarcomas interrogated by wholegenome, whole-exome or targeted cancer gene sequencing ( Fig. 3) . Cancer-related genes mutated in more than one tumor included TP53 (3/15 cases; 20%), KDM6A (2/15 cases; 13%) and MYC (6/15 cases; 40%). Strikingly, we also identified a recurrent missense variant, encoding p.Arg707Gln, in PLCG1 in 3 of 15 cases (20%). PLCG1 encodes phospholipase C γ1 (PLCγ1), a tyrosine kinase signal transducer in the phosphoinositide signaling pathway. Statistical analysis showed that enrichment of the mutation encoding p.Arg707Gln in angiosarcoma was highly significant (q = 0.000002). Capillary sequencing of an additional 15 cases of angiosarcoma indicated that the overall prevalence of mutations encoding p.Arg707Gln was 9% (3/34 cases). No PLCG1 mutations were found in any of the other tumor types investigated here. Notably, all three PLCG1 mutations encoding p.Arg707Gln co-occurred with PTPRB mutations.
The presence of a single recurrent p.Arg707Gln missense variant suggests that PLCγ1 is activated in angiosarcoma. Arg707 lies within the autoinhibitory Src homology 2 (cSH2) domain of PLCγ1 (refs. [16] [17] [18] [19] and provides structural support to this domain. In silico modeling of the mutated protein predicted that the substituted glutamine destabilizes the cSH2 domain, which may result in overactive PLCγ1 (Supplementary Fig. 4) . Disruption of the autoinhibitory l e t t e r s npg l e t t e r s cSH2 domain has been shown to cause immune disorders in mice and humans through constitutive activation of PLCγ enzymes [16] [17] [18] [19] . Interestingly, forward genetic screening of zebrafish has identified plcg1 as a non-redundant regulator of arterial angiogenesis that transduces activation of VEGF signaling 20, 21 , and Plcg1-deficient mice exhibit reduced vasculogenesis 22 . PLCG1 is ubiquitously expressed in normal tissue 17, 19 , and total-RNA sequencing of four angiosarcomas, including two positive for PLCγ1 p.Arg707Gln, demonstrated PLCG1 expression in each case. In the context of existing knowledge about PLCG1, our observations therefore lend support to the hypothesis that activated PLCγ1 drives angiosarcoma, downstream of receptor tyrosine kinases, through constitutive activation of angiogenesis signaling. The effects of PLCG1 mutations on the response to therapeutics targeting tyrosine kinases will be an important future investigation. In addition to screening 15 angiosarcomas for driver mutations, we performed a focused screen for mutations in angiogenesis-related genes in a further 24 angiosarcomas (Supplementary Table 6 ). Considering both cohorts together, 15 of 39 angiosarcomas harbored at least one mutation in an angiogenesis-related gene, highlighting aberrant angiogenesis as a common driver in a subset of tumors. Mutated genes included HRAS, KRAS and NRAS (5/39 cases), PIK3CA (1/39 cases) and FLT4 (1/39 cases). We did not find variants in KDR (VEGFR2), which have previously been reported 23 ( Supplementary Table 1 ). Among other vascular tumors, we identified one Kaposi sarcoma (n = 9) with a PIK3CA driver mutation and one epithelioid hemangioendothelioma (n = 8) with a PTEN driver mutation ( Supplementary Table 1 ). Interestingly, in our series, aberrant angiogenesis was most frequent among secondary and/or MYC-amplified angiosarcomas (12/22 cases), although this observation requires investigation in larger series. There was no evidence of mutual exclusivity of mutations in angiogenesis-related genes ( Fig. 3  and Supplementary Table 1) . In four angiosarcomas, we found more than one angiogenesis-related gene mutated, indicating that targeting treatment exclusively to the tyrosine kinase level might not suffice to overcome aberrant angiogenesis.
As angiosarcoma is a rare tumor, combined efforts to curate larger case series are required to further explore the somatic changes that underpin its pathogenesis. This study, however, provides a first comprehensive insight into the somatic variation in angiosarcoma and identifies frequent mutations in angiogenesis-related genes in a subset of tumors. The next challenge will be to functionally explore these findings in appropriate angiosarcoma models that accommodate the complexity of the driver mutation landscape we report here. It is now indicated to determine the clinical usefulness of PTPRB and PLCG1 as possible biomarkers of secondary disease and as novel therapeutic targets in angiosarcoma.
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Note: Any Supplementary Information and Source Data files are available in the online version of the paper. npg ONLINe MeTHOds Case samples. Informed consent was obtained from all subjects, and ethical approval was obtained from the Cambridgeshire 2 Research Ethics Service (reference 09/H0308/165). Collection and use of patient samples were approved by the appropriate institutional review board (IRB) of each institution.
Whole-genome, whole-exome and targeted cancer gene sequencing. DNA was extracted from 11 angiosarcomas as well as from matched normal tissue derived from the same individuals. Whole-genome sequencing of three cases was performed to average depths of at least 40× and 30× for tumor and normal DNA, respectively, as previously described 24 . Whole-exome sequencing was performed on eight cases as previously described 25 , and at least 70% of the coding sequence was covered by 30×. DNA extracted from an additional 4 tumors that did not have matched normal-tissue DNA was subjected to targeted sequencing of 360 established and putative cancer-related genes using a custommade bait set (Agilent Technologies) for target enrichment (Supplementary Table 7 ). Paired-end sequencing was performed on Illumina HiSeq 2000 or 2500 analyzers. Reads were aligned to the reference human genome (NCBI37) using Burrows-Wheeler Aligner (BWA) on default settings 26 . Reads that were unmapped or were PCR-derived duplicates were excluded from analysis.
Variant detection. The CaVEMan (Cancer Variants through Expectation
Maximization) algorithm was used to call single-nucleotide substitutions 25 .
To call insertions and deletions, we used split-read mapping implemented as a modification of the Pindel algorithm 27 . To call rearrangements, we applied the BRASS (Breakpoint via Assembly) algorithm, which identifies rearrangements by grouping discordant read pairs that point to the same breakpoint event 25 . Post-processing filters were applied to output to improve specificity. Mutations were annotated to Ensembl version 58.
Variant validation.
In whole-genome samples, all coding variants as well as randomly selected mutations-in total, 508 of 15,292 (3.3%) substitutions and 342 of 1,386 (25%) indels-were experimentally validated by wholeexome sequencing or targeted capture with massively parallel sequencing 25 . The overall precision of the catalog of substitutions and indels was thus determined to be at least 94%. Rearrangements were validated by defining the exact location of the breakpoint at nucleotide-level resolution through extraction of split reads across the breakpoint, algorithmically or manually as previously described 25 . Variants called in whole-exome samples were confirmed by visual inspection or resequencing of the exomes.
Angiogenesis gene screen.
Forty-three tumors were included in this screen: 24 angiosarcomas, 9 Kaposi sarcomas, 8 hemangioendotheliomas and 2 hemangiomas. Genes of interest ( Supplementary Table 6 ) and genotyping SNPs were enriched through targeted capture and were sequenced by massively parallel sequencing, as described previously 25 . The PLCG1 mutation encoding p.Arg707Gln was screened for by capillary sequencing (primer sequences available upon request).
RNA sequencing and analysis. Total RNA was isolated from fresh-frozen tissue from four angiosarcomas using TRIzol. Standard Illumina libraries of polyA-selected RNA were sequenced on an Illumina HiSeq 2000 (paired end, 75-bp read length). TopHat 28 (version 1.3.3) was used for alignment. Expression values were derived using Cufflinks 29 (version 1.0.2).
Detection of copy number variation.
Copy number data were derived from whole-genome or whole-exome reads using the ASCAT algorithm (version 2.2) and were validated by SNP6.0 arrays in two cases 30 . In the whole-exome extension study, amplifications were detected by comparing the coverage of candidate genes to the average coverage across the exome, after normalization using matched germline exome sequencing data. A 1.75-fold increase (corresponding to ≥5 copies in 50% of tumor cells) was reported as an amplification. In the targeted extension study, amplifications were detected by comparing the coverage of candidate genes to the coverage of 96 SNPs in the same sample, both normalized against data from a panel of non-tumor samples. A fivefold increase in relative, normalized coverage in tumors was reported as an amplification. To assess LOH in PTPRB, all SNPs that lie within the footprint of the gene were interrogated, and their allele fraction was assessed for deviations from 0.5.
